ALS drug pulled from market in Canada, U.S. after failing late-stage clinical trial
Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.
Amylyx Pharmaceuticals has announced it will withdraw its amyotrophic lateral sclerosis (ALS) drug from the market in Canada and the U.S. following its failure in a late-stage clinical trial.
